First Patient Treated in MB-106 CAR T-cell Trial Now Cancer Free, Mustang Says
News
The first patient treated in Mustang Bio‘s Phase 1/2 clinical trial testing its investigational MB-106 therapy for B-cell non-Hodgkin’s lymphoma has achieved a complete response to treatment — meaning that all signs of the ... Read more